Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice.

The selective estrogen-receptor modulators, or SERMs, chemically diverse nonsteroid compounds, have tertiary structures that permit binding to the estrogen receptor. These compounds have either selective agonist or antagonist effects, depending on the target tissue. This article reviews current information concerning the molecular basis of SERM action and the tissue-selective agonist–antagonist effects of this class of medication. The article also offers a perspective on the therapeutic uses of SERMs and compares the SERMs with estrogen and nonestrogen alternatives.

[1]  E. Barrett-Connor,et al.  Hormones and heart disease in women: Heart and Estrogen/Progestin Replacement Study in perspective. , 1999, The Journal of clinical endocrinology and metabolism.

[2]  J. Cuzick,et al.  Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial , 2002, The Lancet.

[3]  N. Wenger,et al.  Coronary heart disease: an older woman's major health risk , 1997, BMJ.

[4]  J. Gustafsson,et al.  Estrogen receptor β acts as a dominant regulator of estrogen signaling , 2000, Oncogene.

[5]  Lynda H. Powell.  Breast cancer and hormone-replacement therapy. , 1995, The New England journal of medicine.

[6]  D. Wickerham,et al.  Breast cancer chemoprevention: current status and future directions. , 2001, Seminars in oncology.

[7]  R B Mazess,et al.  Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. , 1992, The New England journal of medicine.

[8]  Susan R. Johnson,et al.  Effects of Estrogen or Estrogen/ Progestin Regimens on Heart Disease Risk Factors in Postmenopausal Women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial , 1995 .

[9]  D. McDonnell,et al.  The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. , 1999, Endocrinology.

[10]  P. Goss,et al.  Aromatase inhibitors in the treatment and prevention of breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Helterbrand,et al.  Design and methods of the Raloxifene Use for The Heart (RUTH) study. , 2001, The American journal of cardiology.

[12]  J. Carson,et al.  Risk of venous thromboembolism in users of hormone replacement therapy , 1996, The Lancet.

[13]  C. Cotman,et al.  Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. , 2000, JAMA.

[14]  V. Jordan,et al.  Selective estrogen receptor modulation: a personal perspective. , 2001, Cancer research.

[15]  B. Riggs,et al.  Treatment of Established Postmenopausal Osteoporosis with Raloxifene: A Randomized Trial , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[16]  Robert Selzer,et al.  Estrogen in the Prevention of Atherosclerosis , 2001, Annals of Internal Medicine.

[17]  Brenda L Plassman,et al.  Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. , 2002, JAMA.

[18]  J. Gustafsson,et al.  Estrogen receptor beta--a new dimension in estrogen mechanism of action. , 1999, The Journal of endocrinology.

[19]  Kristen Jepsen,et al.  Combinatorial Roles of the Nuclear Receptor Corepressor in Transcription and Development , 2000, Cell.

[20]  C. Christiansen,et al.  Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. , 1997, The New England journal of medicine.

[21]  Raloxifene, an oestrogen-receptor modulator, prevents decreased constitutive nitric oxide and vasoconstriction in ovariectomized rats. , 2000, European journal of pharmacology.

[22]  A. LaCroix,et al.  Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. , 1998, JAMA.

[23]  Anthony Gamst,et al.  Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer Disease: A Randomized Controlled Trial , 2000 .

[24]  R. Recker,et al.  Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis , 1996 .

[25]  L. Melton,et al.  Role of Low Levels of Endogenous Estrogen in Regulation of Bone Resorption in Late Postmenopausal Women , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[26]  K. Kerlikowske,et al.  Hormone replacement therapy and endometrial cancer risk: a meta-analysis. , 1995, Obstetrics and gynecology.

[27]  G. Hortobagyi,et al.  Update on endocrine therapy for breast cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  J. Cuzick,et al.  Chemoprevention of breast cancer with tamoxifen. , 1996, IARC scientific publications.

[29]  J. Reginster,et al.  Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group. , 2000, The Journal of clinical endocrinology and metabolism.

[30]  Sundeep Khosla,et al.  Sex steroids and the construction and conservation of the adult skeleton. , 2002, Endocrine reviews.

[31]  Zbigniew Dauter,et al.  Molecular basis of agonism and antagonism in the oestrogen receptor , 1997, Nature.

[32]  S. Cummings,et al.  American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  S. Lundgren,et al.  Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the 'nordic' phase III study. , 1997, British Journal of Cancer.

[34]  James N Ingle,et al.  American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  C. Hudis,et al.  Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  R. Legare,et al.  Adjuvant therapy in breast cancer. , 2002, Obstetrics and gynecology clinics of North America.

[37]  E. Winer,et al.  American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  M. Hooper,et al.  Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis , 2000, Osteoporosis International.

[39]  A. Howell,et al.  Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer , 1997, International journal of cancer.

[40]  C. Schneeberger,et al.  Production and actions of estrogens. , 2002, The New England journal of medicine.

[41]  K. Dahlman-Wright,et al.  Estrogen Receptor (ER)-β Reduces ERα-Regulated Gene Transcription, Supporting a “Ying Yang” Relationship between ERα and ERβ in Mice , 2003 .

[42]  M Carlquist,et al.  Structural insights into the mode of action of a pure antiestrogen. , 2001, Structure.

[43]  C. Christiansen,et al.  Raloxifene and estrogen reduces progression of advanced atherosclerosis--a study in ovariectomized, cholesterol-fed rabbits. , 2001, Atherosclerosis.

[44]  S. Azen,et al.  Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. , 2001, Annals of internal medicine.

[45]  L. Arrighi,et al.  [Treatment of breast cancer]. , 1971, Prensa medica argentina.

[46]  J. Lindgren,et al.  Effects of anti-estrogens on bone in castrated and intact female rats , 1987, Breast Cancer Research and Treatment.

[47]  D. Cox,et al.  Raloxifene and estrogen inhibit neointimal thickening after balloon injury in the carotid artery of male and ovariectomized female rats. , 2000, Journal of cardiovascular pharmacology.

[48]  Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. , 1994, Archives of internal medicine.

[49]  D. Reboussin,et al.  Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. , 2000, The New England journal of medicine.

[50]  D. Hayes,et al.  Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  S. Legha,et al.  Tamoxifen in the treatment of breast cancer. , 1988, Annals of internal medicine.

[52]  I. Reid,et al.  The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women. , 1995, The American journal of medicine.

[53]  T. Powles,et al.  Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  P. Goss,et al.  Estrogen and the risk of breast cancer. , 2001, The New England journal of medicine.

[55]  A. Buzdar,et al.  Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  David A. Agard,et al.  The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen , 1998, Cell.

[57]  R. Turner,et al.  Tamoxifen inhibits osteoclast-mediated resorption of trabecular bone in ovarian hormone-deficient rats. , 1988, Endocrinology.

[58]  S. Paul,et al.  Raloxifene and estradiol benzoate both fully restore hippocampal choline acetyltransferase activity in ovariectomized rats , 1999, Brain Research.

[59]  Harry K. Genant,et al.  Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene: Results From a 3-year Randomized Clinical Trial , 2000 .

[60]  B. O’Malley,et al.  Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. , 1997, Molecular endocrinology.

[61]  Myles Brown,et al.  Molecular Determinants for the Tissue Specificity of SERMs , 2002, Science.

[62]  K. Grandien,et al.  Printed in U.S.A. Copyright © 1997 by The Endocrine Society Comparison of the Ligand Binding Specificity and Transcript Tissue Distribution of Estrogen Receptors � and � , 2022 .

[63]  J. Garland.  The New England Journal of Medicine. , 1961, Canadian Medical Association journal.

[64]  J. Bryant,et al.  Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. , 2001, Journal of the National Cancer Institute.

[65]  K. Korach,et al.  Estrogen receptor null mice: what have we learned and where will they lead us? , 1999, Endocrine reviews.

[66]  T. Powles,et al.  Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial , 1998, The Lancet.

[67]  David Greenblatt,et al.  Treatment of Postmenopausal Osteoporosis , 2005, Pharmacotherapy.

[68]  S. Cummings,et al.  The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women: Results From the MORE Randomized Trial , 2000 .

[69]  P. Boyle,et al.  Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women , 1998, The Lancet.

[70]  R. Gray,et al.  The optimal duration of adjuvant tamoxifen treatment for breast cancer remains uncertain: randomize into aTTom. , 1997, Clinical oncology (Royal College of Radiologists (Great Britain)).

[71]  B. McEwen,et al.  Estrogen actions in the central nervous system. , 1999, Endocrine reviews.

[72]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[73]  L. Kuller,et al.  Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. , 1998, JAMA.

[74]  M. Anthony,et al.  Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. , 1998, The Journal of clinical endocrinology and metabolism.

[75]  J. Satagopan,et al.  Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. , 2002, The New England journal of medicine.

[76]  E. Vittinghoff,et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.

[77]  D. McDonnell,et al.  The Molecular Pharmacology of SERMs , 1999, Trends in Endocrinology & Metabolism.

[78]  M Baum,et al.  First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial , 2002, The Lancet.

[79]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[80]  J. Reginster,et al.  Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group. , 2000, The Journal of clinical endocrinology and metabolism.

[81]  T. Walsh,et al.  Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. , 2001, JAMA.

[82]  E. Vittinghoff,et al.  Postmenopausal Hormones and Incontinence: The Heart and Estrogen/Progestin Replacement Study , 2001, Obstetrics and gynecology.

[83]  R. Lanz,et al.  Nuclear receptor coregulators: cellular and molecular biology. , 1999, Endocrine reviews.

[84]  E. Barrett-Connor,et al.  Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. , 2002, JAMA.

[85]  Ose,et al.  Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events* , 2002 .

[86]  H Grøn,et al.  Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[87]  Osborne Ck,et al.  Tamoxifen in the Treatment of Breast Cancer , 1998 .

[88]  K Yaffe,et al.  Cognitive function in postmenopausal women treated with raloxifene. , 2001, The New England journal of medicine.

[89]  P. Hietanen,et al.  Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. , 1998, The Journal of clinical endocrinology and metabolism.

[90]  Paul Cleary,et al.  Use of Hormone Replacement Therapy by Postmenopausal Women in the United States , 1999, Annals of Internal Medicine.

[91]  J. Robertson,et al.  Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[92]  R. Tracy,et al.  The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. , 2000, The Journal of clinical endocrinology and metabolism.

[93]  M. Taskinen,et al.  Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[95]  D. Fowlkes,et al.  Peptide antagonists of the human estrogen receptor. , 1999, Science.

[96]  H. Mouridsen,et al.  Femoral fractures in postmenopausal breast cancer patients treated with adjuvant tamoxifen , 2005, Breast Cancer Research and Treatment.

[97]  D. McDonnell,et al.  The Estrogen Receptor ␤-isoform (er␤) of the Human Estrogen Receptor Modulates Er␣ Transcriptional Activity and Is a Key Regulator of the Cellular Response to Estrogens and Antiestrogens* , 2022 .

[98]  J-A,et al.  Estrogen receptor (cid:1) – a new dimension in estrogen mechanism of action , 1999 .

[99]  B. L. Riggs,et al.  Bone Turnover Matters: The Raloxifene Treatment Paradox of Dramatic Decreases in Vertebral Fractures Without Commensurate Increases in Bone Density , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[100]  D. DeMets,et al.  Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. , 1991, Annals of internal medicine.

[101]  C. Christiansen,et al.  Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. , 2000, Archives of internal medicine.

[102]  E. Vittinghoff,et al.  Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial. , 2002, JAMA.

[103]  E. Siris,et al.  Effects of tamoxifen on spinal bone density in women with breast cancer. , 1989, Journal of the National Cancer Institute.

[104]  J. Compston,et al.  Estrogen Receptors α and β Are Differentially Expressed in Developing Human Bone1 , 2001 .

[105]  J. Abrams.  Tamoxifen: five versus ten years--is the end in sight? , 2001, Journal of the National Cancer Institute.

[106]  Susan L Neuhausen,et al.  Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. , 2002, The New England journal of medicine.